Michelle Petri, MD MPH

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Emergent Biosciences
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Exo Therapeutics
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
    Relationship end date:
    12/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Gentibio
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    GSK
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Horizon Therapeutics
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    iCell Gene Therapeutics
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    IQVIA
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
    Relationship end date:
    12/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Idorsia Pharmaceuticals
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
    Relationship end date:
    07/31/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Kira Pharmaceuticals
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
    Relationship end date:
    03/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Eli Lilly
    Topic:
    SLE
    Date added:
    01/21/2024
    Date updated:
    01/21/2024
    Relationship end date:
    12/31/2022

Pages

Return to 2024 Inova Fairfax MGR (Enduring Material): Update on SLE Classification, Treatment, and Complications